{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:47:20Z","timestamp":1758991640000},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T00:00:00Z","timestamp":1242864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s10549-009-0410-5","type":"journal-article","created":{"date-parts":[[2009,5,20]],"date-time":"2009-05-20T06:40:52Z","timestamp":1242801652000},"source":"Crossref","is-referenced-by-count":13,"title":["Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"118","author":[{"suffix":"II","given":"John W.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi J.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick V.","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Encarnacion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce A.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,21]]},"reference":[{"key":"410_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0305-7372(03)00139-7","volume":"30","author":"MP Decatris","year":"2004","unstructured":"Decatris MP, Sundar S, O\u2019Byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 30:53\u201381. doi:\n                    10.1016\/S0305-7372(03)00139-7","journal-title":"Cancer Treat Rev"},{"key":"410_CR2","doi-asserted-by":"publisher","first-page":"23899","DOI":"10.1074\/jbc.C000276200","volume":"275","author":"A Bhattacharyya","year":"2000","unstructured":"Bhattacharyya A, Ear US, Koller BH et al (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899\u201323903. doi:\n                    10.1074\/jbc.C000276200","journal-title":"J Biol Chem"},{"key":"410_CR3","first-page":"6221","volume":"63","author":"JE Quinn","year":"2003","unstructured":"Quinn JE, Kennedy RD, Mullan PB, Gilmore PM et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221\u20136228","journal-title":"Cancer Res"},{"key":"410_CR4","unstructured":"Garber JE, Richardson A, Harris LN, et al. (2006) Neo-adjuvent cisplatin (CDDP) in \u201ctriple-negative\u201d breast cancer (BC). San Antonio Breast Cancer Symposium, abstr 3074"},{"key":"410_CR5","first-page":"2581","volume":"53","author":"LR Kelland","year":"1993","unstructured":"Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53:2581\u20132586","journal-title":"Cancer Res"},{"issue":"9","key":"410_CR6","first-page":"981","volume":"1","author":"SY Sharp","year":"1995","unstructured":"Sharp SY, Rogers PM, Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1(9):981\u2013989","journal-title":"Clin Cancer Res"},{"key":"410_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00685835","volume":"32","author":"WC Rose","year":"1994","unstructured":"Rose WC, Crosswell AR, Schurig JE et al (1994) Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 32:197\u2013203. doi:\n                    10.1007\/BF00685835","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"410_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.canlet.2007.08.019","volume":"258","author":"MB Gariboldi","year":"2007","unstructured":"Gariboldi MB, Ravizza R, Molteni R et al (2007) Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 258(2):181\u2013188. doi:\n                    10.1016\/j.canlet.2007.08.019","journal-title":"Cancer Lett"},{"key":"410_CR9","unstructured":"GPC Biotech Inc. April 2004. Satraplatin (JM-216) Bis (acetato) ammine dichloro (cyclohexylamine) platinum (IV). Clinical Investigator\u2019s Brochure Version 1"},{"issue":"7","key":"410_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1586\/14737140.6.7.973","volume":"6","author":"H Choy","year":"2006","unstructured":"Choy H (2006) Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 6(7):973\u2013982. doi:\n                    10.1586\/14737140.6.7.973","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"410_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000084201","volume":"68","author":"CN Sternberg","year":"2005","unstructured":"Sternberg CN, Whelan P, Hetherington J et al (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68(1):2\u20139. doi:\n                    10.1159\/000084201","journal-title":"Oncology"},{"key":"410_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205\u2013216. doi:\n                    10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"key":"410_CR13","unstructured":"Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events v3.0 (CTCAE). URL: \n                    http:\/\/ctep.cancer.gov\/reporting\/ctc_v30.html\n                    \n                  . Accessed 30 Sep 2008"},{"key":"410_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310. doi:\n                    10.1016\/0197-2456(89)90015-9","journal-title":"Control Clin Trials"},{"issue":"8","key":"410_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573\u2013584. doi:\n                    10.1038\/nrc2167","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"410_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/BF00254257","volume":"11","author":"K Kolari\u0107","year":"1983","unstructured":"Kolari\u0107 K, Roth A (1983) Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11(2):108\u2013112. doi:\n                    10.1007\/BF00254257","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"410_CR17","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1200\/JCO.1988.6.12.1811","volume":"6","author":"GW Sledge Jr","year":"1988","unstructured":"Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6(12):1811\u20131814","journal-title":"J Clin Oncol"},{"issue":"Suppl A","key":"410_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0305-7372(85)90015-5","volume":"12","author":"KR Harrap","year":"1985","unstructured":"Harrap KR (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12(Suppl A):21\u201333","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"410_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF00688868","volume":"27","author":"K Kolari\u0107","year":"1991","unstructured":"Kolari\u0107 K, Vukas D (1991) Carboplatin activity in untreated metastatic breast cancer patients\u2013results of a phase II study. Cancer Chemother Pharmacol 27(5):409\u2013412. doi:\n                    10.1007\/BF00688868","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"410_CR20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1992.10.3.433","volume":"10","author":"M Mart\u00edn","year":"1992","unstructured":"Mart\u00edn M, D\u00edaz-Rubio E, Casado A et al (1992) Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 10(3):433\u2013437","journal-title":"J Clin Oncol"},{"issue":"9","key":"410_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jjco\/hyd102","volume":"30","author":"T Kurata","year":"2000","unstructured":"Kurata T, Tamura T, Sasaki Y et al (2000) Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 30(9):377\u2013384. doi:\n                    10.1093\/jjco\/hyd102","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"410_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3816\/CBC.2001.n.022","volume":"2","author":"M Mart\u00edn","year":"2001","unstructured":"Mart\u00edn M (2001) Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2(3):190\u2013208. doi:\n                    10.3816\/CBC.2001.n.022","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"410_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/187152007779314071","volume":"7","author":"I Ott","year":"2007","unstructured":"Ott I, Gust R (2007) Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem 7(1):95\u2013110. doi:\n                    10.2174\/187152007779314071","journal-title":"Anticancer Agents Med Chem"},{"issue":"suppl 2","key":"410_CR24","first-page":"23","volume":"18","author":"M Mart\u00edn","year":"1991","unstructured":"Mart\u00edn M, D\u00edaz-Rubio E, Casado A et al (1991) Phase II study of carboplatin in advanced breast cancer: preliminary results. Semin Oncol 18(suppl 2):23\u201327","journal-title":"Semin Oncol"},{"issue":"11","key":"410_CR25","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.1993.11.11.2112","volume":"11","author":"ME O\u2019Brien","year":"1993","unstructured":"O\u2019Brien ME, Talbot DC, Smith IE (1993) Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11(11):2112\u20132117","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-009-0410-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0410-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T21:16:10Z","timestamp":1581974170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-009-0410-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,21]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s10549-009-0410-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,21]]},"article-number":"361"}}